Johnson & Johnson (J&J) and its US-based Janssen Pharmaceutical Companies have agreed to pay $63m to Nevada state in the US and its participating subdivisions for resolving its role in the opioid epidemic.

The settlement agreement was announced by Nevada Attorney General Aaron Ford.

With the deal, the company is no longer involved in the ongoing litigation by Nevada and its subdivisions.

About 95% of the settlement amount will be paid by J&J by the end of this year.

According to the State of Nevada, this agreement has a substantially shorter term as against settlements with other US states and the company.

Several of them are to be paid over a nine-year period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal is consistent with the previously reported US-wide agreement to settle opioid claims.

In a press statement, J&J said: “The dollar amount to be received by the state is the pro-rated share it would have received under this agreement, which will be deducted from the all-in settlement amount.

“This settlement is not an admission of any liability or wrongdoing and the company will continue to defend against any litigation that the final agreement does not resolve.”

The company also noted that the commercialisation and promotion of key prescription opioid drugs were responsible and suitable.

Since the launch of Duragesic, Nucynta And Nucynta ER, these drugs accounted for under 1% of total opioid prescriptions in the state of Nevada and the US.

Currently, J&J does not market prescription opioid drugs in the US.

In June and October last year, J&J entered similar $230m and $297m settlement agreements with the New York State and Texas, respectively, to resolve claims linked to opioids.